CannabisNewsBreaks

TuesdayAug 16, 2022 11:10 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Releases Financial Results for H1 2022

Flora Growth (NASDAQ: FLGC), a manufacturer and distributor of global cannabis products and brands, is reporting its financial and corporate results for the six months ending June 30, 2022. Highlights of the report include revenue for the company increasing 604% from the same period last year, reaching ~$15 million while gross profit for the company increased to ~$7 million, an increase of 547%. In the report, the company reaffirmed its 2022 revenue guidance of $35 million to $45 million, which represents an increase in projected revenue of between 300% to 400%. “In the first half of 2022, Flora delivered on…

Continue Reading

ThursdayAug 11, 2022 12:16 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Discusses Biotech Industry Valuation Metrics

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company today issued information to its stakeholders as an aid to conveniently research and understand various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. “Biotech companies with little to no revenue can still be worth billions,” Raphael Rottgen, CFA, FRM, was quoted in the press release. “While valuations can be extremely low or extremely high, there is often underlying logic in identifying risks and arriving at those valuations. Developing new drugs can have significant costs of over $1 billion and can take…

Continue Reading

WednesdayAug 10, 2022 12:37 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of a positive full written response from the Food and Drug Administration (“FDA”) from its pre-Investigational New Drug (“Pre-IND”) meeting regarding DehydraTECH-CBD for the treatment of hypertension. According to the update, the FDA confirmed agreement with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway for its program. This is advantageous because the abbreviated pathway, as it is often described, typically enables a faster route to commercial approval than the traditional 505(b)(1) NDA pathway. “We are very pleased to have received…

Continue Reading

WednesdayAug 10, 2022 12:21 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Earnings Conference Call, Webcast

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, has scheduled a conference call and webcast to discuss its earnings for the first half of 2022. The call is slated for Monday, Aug. 15, 2022, at 4:30 p.m. ET. the company plans to release its financial report and numbers prior to the call. During the call, company officials will discuss the financial and operations results as well as provide an update on the company’s operations, house of brands and life sciences strategies; the event will also include time for a Q&A. An…

Continue Reading

TuesdayAug 09, 2022 12:40 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the appointment of Nicole Lemerond to its board of directors, effective immediately. Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. Throughout her career, she has established and led health care groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group. Concurrent with Lemerond’s appointment, Adam Cutler has decided to transition off the board of directors. Cutler has served…

Continue Reading

TuesdayAug 02, 2022 1:53 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Helping Innovators of Today, Leaders of Tomorrow

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) patented DehydraTECH(TM) has been regarded as one of the most innovative drug delivery technologies in years, proving useful in delivering a wide range of active pharmaceutical ingredients in a more palatable and effective way. Studies have also demonstrated DehydraTECH’s ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances, with cannabinoids by as much as 27x compared to standard industry formulations, a benefit that opens significant possibilities for important drug delivery. “DehydraTECH’s application in the cannabis sector is seeing a boom, particularly with the recent expansion of Boldt Runners Corporation, a…

Continue Reading

TuesdayAug 02, 2022 11:39 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Enters Joint Venture with Colombia’s Largest Indigenous Tribe

Flora (NASDAQ: FLGC) is a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands. The company today announced a joint venture agreement with Pharma Indigena Misak Manasr Sas (“Manasr”), the largest indigenous tribe in Colombia, on the development of cultivation best practices, manufacturing, export, and marketing of cannabis and cannabis containing products. “We are honored to be given opportunity to work hand-in-hand with the Misak people,” said Luis Merchan, Flora’s chairman and CEO. “Through this partnership, we will collaborate with the tribe on the processing and distribution of their Colombian-grown cannabis while offering Manasr a powerful platform…

Continue Reading

WednesdayJul 27, 2022 1:32 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Poised with Strong In-Market Brand Portfolio, Cultivation and Export Capabilities

Flora Growth Corp. (NASDAQ: FLGC) recently reported that its board of directors had authorized the repurchase of up to $5 million of its outstanding common shares. “These recent developments highlight Flora management’s confidence in where the company is headed and its potential for growth as the year progresses. It also assures shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so. As such, this only emphasizes Flora’s value as a good investment,” a recent article reads. “While making the announcement, Luis Merchan, Flora’s chairman and CEO, noted: ‘Flora continues to move assertively to execute…

Continue Reading

WednesdayJul 27, 2022 12:08 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing with its DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been completed in its multi-week human clinical hypertension study HYPER-H21-4. According to the update, no serious adverse events have been reported as a result of the dosing. “We are extremely pleased that dosing has been completed on time in this multi-week clinical study without any serious adverse events having occurred,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this…

Continue Reading

TuesdayJul 26, 2022 1:26 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its exclusive* Japanese licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand “Ko.” According to the update, the brand was launched for the Japanese consumer market on July 21, 2022. Premier will create its own e-commerce infrastructure and digital marketing campaigns in collaboration with its parent company, Premier Anti-Aging Co. Ltd., which is listed on the Tokyo Stock Exchange (4934:JP). The Ko brand will contain CBD and other botanical extracts and is focused on…

Continue Reading